News and Trends 17 Jan 2023 Ascletis phase I COVID trial progressing Ascletis Pharma Inc. has announced the dosing of four healthy subjects in its multiple-dose escalation phase I clinical trial of oral 3-chymotrypsin like protease (3CLpro) inhibitor ASC11 in combination with 100 mg ritonavir tablets for COVID-19. The phase I clinical trial is expected to enroll 72 healthy subjects, including 60 subjects in single-dose escalation cohorts […] January 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2023 Poolbeg expands POLB 001 into oncology Poolbeg Pharma has announced the strategic expansion of POLB 001 into oncology. POLB 001 is a strain agnostic, small molecule immunomodulator being studied to address the unmet medical need for a treatment for severe influenza. While investigating the role of cytokine release syndrome (CRS) in severe influenza, Poolbeg discovered data specific to the overt immune […] January 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2023 Multus Biotechnology closes $9.5M funding to bring cultivated meat closer to price parity Multus Biotechnology Limited, a U.K.-based start-up creating ingredients for the affordable scale-up of cellular agriculture, has completed a £7.9 million ($9.5 million) funding round led by Mandi Ventures. Other investors include SOSV, Big Idea Ventures and SynBioVen, alongside Asahi Kasei, a global company that contributes to a sustainable society by tackling evolving challenges in materials, […] January 17, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2023 EverImmune launches trial for oncobiotic lung and kidney cancer drug candidate EverImmune, a clinical-stage biotechnology company specialized in the development of live biotherapeutic products in the field of microbiota oncology, says the first patient has been treated in its phase I clinical trial (EV 2101) evaluating Oncobax AK in lung and kidney cancer patients. The aim of the trial is to assess the toxicity and efficacy […] January 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jan 2023 TTP spinout Cellular Origins to focus on cell and gene therapies TTP plc, a technology and product development company, has announced the launch of Cellular Origins. Cellular Origins is a TTP spin-out, created to enable scalable, cost-effective and efficient manufacture of cell and gene therapies. Cellular Origins’ proprietary technology addresses the current barriers associated with the manufacture of advanced therapies that are in late-stage development, enabling […] January 17, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Sponsored by WuXi Advanced Therapies 17 Jan 2023 Navigating cell and gene therapy manufacturing with a long-term partnership Cell and gene therapies have proven to be promising treatments for cancers and genetic diseases, but developers face key challenges before these treatments reach patients’ bedsides. A long-term partnership with a contract development and manufacturing organization (CDMO) can ease the path life science companies travel from manufacturing these life-changing treatments and bringing them to the […] January 17, 2023 - 7 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2023Beyond Biotech podcast 29: Janssen, Knowledge Gate This week, our guests are Viktoriya Vasilenko, Knowledge Gate co-founder and CEO; and Avery Ince, vice president, medical affairs, cardiovascular & metabolism at Janssen Scientific Affairs, LLC. Study confirms benefit of XARELTO (rivaroxaban) for secondary prevention of venous thromboembolism in cancer patients The Janssen Pharmaceutical Companies of Johnson & Johnson has revealed observational data from […] January 12, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2023 Anticancer drugs could lead to new sepsis treatment Researchers at the Instituto Gulbenkian de Ciência (IGC) in Oeiras, Portugal, say because anti-cancer drugs limit inflammation, they could be a potential treatment for sepsis. The study, published in eLife, reveals that the class of drugs used in cancer treatment limit the unrestrained production of inflammatory mediators by the immune system. The discovery positions these […] January 12, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2023 JPND launches €16.5M call for research on OMICS data for neurodegenerative diseases The EU Joint Programme – Neurodegenerative Disease Research (JPND) initiative has issued a call for multinational research on large scale analysis of OMICS data for drug-target finding in neurodegenerative diseases. Neurodegenerative diseases are debilitating and largely untreatable conditions that are strongly linked with age. Worldwide, there are estimated to be 50 million people with Alzheimer’s […] January 12, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2023 Breast cancer most studied disease area in 2022 Phesi, a global provider of patient-centric data analytics, has released the results of its global analysis of all clinical trials conducted in 2022. The report, which analyzed 80,917 trial records, reveals that breast cancer retained its position as the most-studied disease area, followed by COVID-19. Three of the top five most-studied disease areas fell within oncology, […] January 12, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2023 Collaboration to boost pandemic preparedness, structure-based drug discovery and vaccine design A new Memorandum of Understanding (MoU) to facilitate collaboration in the field of pandemic preparedness and to promote further cooperation between the University of Oxford and Diamond Light Source has been announced. The University of Oxford and Diamond Light Source already have many links but now intend to develop their collaborative work to address multiple […] January 12, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2023 Team wins $149M contract for National Institute of Neurological Disorders and Stroke A team consisting of Battelle, AmplifyBio and Andelyn Biosciences has won a seat on an eight-year, $149 million indefinite delivery, indefinite quantity (IDIQ) contract vehicle for the National Institute of Neurological Disorders and Stroke in the U.S. As one of the prime contractors on the multi-award IDIQ, the team will provide manufacturing and nonclinical support […] January 12, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email